INVENTIVA SA - ADR (IVA)
US46124U1079 - ADR
IVA gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. IVA has a bad profitability rating. Also its financial health evaluation is rather negative. IVA shows excellent growth, but is valued quite expensive already.
1. Profitability
1.1 Basic Checks
IVA had negative earnings in the past year.
IVA had a negative operating cash flow in the past year.
In the past 5 years IVA always reported negative net income.
IVA had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
IVA has a worse Return On Assets (-154.72%) than 87.18% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -154.72% | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)-37.23%
ROA(5y)-41.37%
ROE(3y)-68.48%
ROE(5y)-66.6%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IVA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
IVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IVA has been increased compared to 1 year ago.
Compared to 5 years ago, IVA has more shares outstanding
IVA has a worse debt/assets ratio than last year.
2.2 Solvency
IVA has an Altman-Z score of -7.09. This is a bad value and indicates that IVA is not financially healthy and even has some risk of bankruptcy.
IVA has a Altman-Z score of -7.09. This is in the lower half of the industry: IVA underperforms 69.74% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -7.09 |
ROIC/WACCN/A
WACC7.05%
2.3 Liquidity
IVA has a Current Ratio of 1.39. This is a normal value and indicates that IVA is financially healthy and should not expect problems in meeting its short term obligations.
IVA has a Current ratio of 1.39. This is amonst the worse of the industry: IVA underperforms 85.30% of its industry peers.
A Quick Ratio of 1.38 indicates that IVA should not have too much problems paying its short term obligations.
IVA's Quick ratio of 1.38 is on the low side compared to the rest of the industry. IVA is outperformed by 83.76% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.39 | ||
| Quick Ratio | 1.38 |
3. Growth
3.1 Past
The earnings per share for IVA have decreased strongly by -88.49% in the last year.
Looking at the last year, IVA shows a very strong growth in Revenue. The Revenue has grown by 240.92%.
Measured over the past years, IVA shows a very strong growth in Revenue. The Revenue has been growing by 20.48% on average per year.
EPS 1Y (TTM)-88.49%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-81.94%
Revenue 1Y (TTM)240.92%
Revenue growth 3Y20.29%
Revenue growth 5Y20.48%
Revenue growth Q2Q2614.29%
3.2 Future
The Earnings Per Share is expected to grow by 16.07% on average over the next years. This is quite good.
IVA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 45.06% yearly.
EPS Next Y-27.7%
EPS Next 2Y-20.09%
EPS Next 3Y-9.26%
EPS Next 5Y16.07%
Revenue Next Year-7.76%
Revenue Next 2Y-36.68%
Revenue Next 3Y2.55%
Revenue Next 5Y45.06%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
IVA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IVA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
IVA's earnings are expected to decrease with -9.26% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-20.09%
EPS Next 3Y-9.26%
5. Dividend
5.1 Amount
No dividends for IVA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INVENTIVA SA - ADR
NASDAQ:IVA (4/19/2024, 9:31:53 AM)
3.3
-0.15 (-4.35%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap170.43M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -154.72% | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.2
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.39 | ||
| Quick Ratio | 1.38 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-88.49%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-27.7%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)240.92%
Revenue growth 3Y20.29%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y